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Available online 18 August 2017N-methyl-D-aspartate receptor (NMDAR) subunit composition strictly commands receptor function and pharma-
cological responses. Changes in NMDAR subunit composition have been documented in brain disorders such as
Parkinson's disease (PD) and levodopa (L-DOPA)-induced dyskinesias (LIDs), where an increase of NMDAR
GluN2A/GluN2B subunit ratio at striatal synapses has been observed. A therapeutic approach aimed at rebalancing
NMDAR synaptic composition represents a valuable strategy for PD and LIDs. To this, the comprehension of the
molecular mechanisms regulating the synaptic localization of different NMDAR subtypes is required.
We have recently demonstrated that Rabphilin 3A (Rph3A) is a new binding partner of NMDARs containing the
GluN2A subunit and that it plays a crucial function in the synaptic stabilization of these receptors. Considering
that protein-protein interactions govern the synaptic retention of NMDARs, the purpose of this work was to ana-
lyse the role of Rph3A and Rph3A/NMDAR complex in PD and LIDs, and tomodulate Rph3A/GluN2A interaction to
counteract the aberrantmotor behaviour associated to chronic L-DOPA administration. Thus, an array of biochem-
ical, immunohistochemical and pharmacological tools together with electron microscopy were applied in this
study. Here we found that Rph3A is localized at the striatal postsynaptic density where it interacts with GluN2A.
Notably, Rph3A expression at the synapse and its interaction with GluN2A-containing NMDARs were increased
in parkinsonian rats displaying a dyskinetic profile. Acute treatment of dyskinetic animals with a cell-permeable
peptide able to interfere with Rph3A/GluN2A binding significantly reduced their abnormal motor behaviour.
Altogether, our findings indicate that Rph3A activity is linked to the aberrant synaptic localization of GluN2A-
expressingNMDARs characterizing LIDs. Thus,we suggest that Rph3A/GluN2A complex could represent an inno-
vative therapeutic target for those pathological conditions where NMDAR composition is significantly altered.
© 2017 Published by Elsevier Inc.Keywords:
N-methyl-D-aspartate receptor
Levodopa-induced dyskinesias
Pharmacological target
Cell-permeable peptidesiomolecular Sciences, University
.
om).1. Introduction
The control of abnormal movements still represents a therapeutic
challenge in the field of Parkinson's disease (PD) and levodopa (L-
DOPA)-induced dyskinesias (LIDs; Bastide et al. 2015). Considering that
excessive glutamatergic transmission at the corticostriatal synapse and
aberrant activation of NMDA-type of glutamate receptors (NMDARs)
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2015; Mellone and Gardoni 2013; Errico et al. 2011), a therapeutical ap-
proach based on the classical NMDAR antagonists has been investigated.
In spite of both preclinical and clinical studies sharing a general agree-
ment on the potential of these compounds to attenuate PDmotor symp-
toms and reduce LIDs, unfortunately, they are mostly not well tolerated
by primates. Amantadine, a low-affinity non-competitive antagonist of
NMDARs (Kornhuber et al. 1991) has shown a moderate anti-
dyskinetic activity (Da Silva-Júnior et al. 2005; Luginger et al. 2000;
Ory-Magne et al. 2014; Snow et al. 2000; Wolf et al. 2010; Thomas
et al. 2004). Taking into account that changes in the trafficking/subcellu-
lar localization of specific NMDAR subunits at the striatal postsynaptic
membrane correlates with the motor behaviour abnormalities observed
in models of LIDs (Gardoni et al. 2006, 2012) and dyskinetic PD patients
(Mellone et al. 2015), an innovative strategy rescuing the physiological
subunit composition of synaptic NMDARs may represent the step
forward.
Synaptic retention of NMDAR subtypes is controlled by their subunit
composition and their interacting proteins. Even if it is well-known that
protein–protein interactions govern the synaptic retention of NMDARs
(Paoletti et al. 2013), only few studies focused on the mechanisms con-
trolling NMDAR synaptic abundance as a potential pharmacological tar-
get in central nervous systemdisorders (Hill et al. 2012). Remarkably,we
recently demonstrated that an increase in synaptic NMDAR GluN2A/
GluN2B subunit ratio in the striatum correlates with the motor behav-
iour abnormalities observed in rat models of PD and LIDs (Gardoni
et al. 2006, 2012). These findings were confirmed in the striatum of dys-
kinetic monkeys and PD patients (Mellone et al. 2015). Moreover, the
systemic treatment with a peptide, able to interfere with the interaction
between GluN2A and PSD-95, reduces the percentage of parkinsonian
rats developing LIDs (Gardoni et al. 2012) and ameliorates the dyskinetic
behaviour in L-DOPA-treated MPTP-monkeys (Mellone et al. 2015). In-
terestingly, themodulation of PSD-95 interaction alsowith D1 dopamine
receptor has been correlated with the onset of a dyskinetic behaviour
(Porras et al. 2012) thus suggesting that the activity of scaffolding pro-
teins regulating receptor trafficking/stabilization at the corticostriatal
synapse could be considered a putative target for the treatment of dyski-
nesia in PD patients (Mellone and Gardoni 2013; Gardoni and Di Luca
2015).
Furthermore, we have very recently described Rabphilin-3A (Rph3A)
as a newGluN2A-binding partner (Stanic et al. 2015). Rph3Awas known
as a synaptic vesicle-associated protein involved in the regulation of exo-
and endocytosis processes at presynaptic sites (Burns et al. 1998). Our
work showed that Rph3A is also enriched at dendritic spineswhere it in-
teracts with both GluN2A C-terminal domain and PSD-95 (Stanic et al.
2015). Rph3A silencing in neurons was able to reduce the surface locali-
zation of synaptic GluN2A subunit and NMDAR currents. Moreover,
disrupting GluN2A/Rph3A interaction with interfering peptides leads to
a decrease of GluN2A levels at dendritic spines (Stanic et al. 2015).
These results indicate that GluN2A/Rph3A/PSD-95 trimeric complex pro-
motes GluN2A-containing NMDAR retention at the postsynaptic
membrane.
In this frame, here we characterize the role of Rph3A and Rph3A/
GluN2A complex in PD andLIDs. In particular,we explored the possibility
of interfering with this protein-protein interaction in order to reduce
dyskinetic motor behaviour in 6-OHDA-lesioned rats with a dyskinetic
profile following chronic L-DOPA treatment.
2. Materials and methods
2.1. 6-hydroxydopamine (6-OHDA) rat model
Adultmale SpragueDawley rats (125–175 g; Charles River Laborato-
ries, Calco, Italy)were used in this study. Ratsweremaintained on a 12 h
light/dark cycle in a temperature-controlled room (22 °C) with free ac-
cess to food and water. All procedures were carried out in accordancewith the current European Law (2010/6106/EU) and they were also ap-
proved by the Italian Ministry of Health (as indicated in D.Lgs. n. 295/
2012-A and in D.Lgs. n. 26/2014 - Authorization 327/2015-PR).
Rats underwent a unilateral stereotaxic injection of 6-OHDA (Sigma-
Aldrich, St. Louis, MO, USA; 12 μg at 4 μg/μl, rate of injection 0.38 μl/min)
in the medial forebrain bundle (MFB; AP:−4.4, L: +1.2; DV:−7.5) as
previously reported (Mellone et al. 2015). Two weeks later, the entity
of the nigrostriatal lesionwas testedwith 0.05mg/kg apomorphine chal-
lenge (Sigma-Aldrich; subcutaneous injection, s.c.), and the contralateral
turns were counted for 40 min. Animals which performed at least 200
contralateral turns following apomorphine injection were used for the
study (Paillé et al, 2010). These rats displayed N95% loss of nigrostriatal
fibers and were classified as fully lesioned. The severity of the lesion
was also evaluated byWestern blot (WB) analysis measuring the striatal
levels of tyrosine hydroxylase (TH; #AB152, Millipore).
Fully lesioned rats were treated with 6 mg/kg L-DOPA (Sigma-Al-
drich) in combination with 6 mg/kg benserazide (Sigma-Aldrich), 1 s.c
injection/day for 14 days. L-DOPA-induced abnormal involuntary move-
ments (AIMs) were evaluated on days 4, 7, 10 and 14 of L-DOPA admin-
istration using a highly validated rat AIMs scale (Cenci et al. 1998;
Lundblad et al. 2002; Gardoni et al. 2006) and animals were classified
as dyskinetic and non dyskinetic. Dyskinetic rats underwent a single ste-
reotaxic injection of 5 nmol TAT-2A40 or 5 nmol TAT-Scr peptides in the
striatum ipsilateral to the 6-OHDA lesion (5 μl; rate of injection 0.5 μl/
min; AP: +0.2, L: +3.5, DV:−5.7) between days 15 and 16 of L-DOPA
treatment. Dyskinetic rats treated onlywith L-DOPAwere used as further
control. In all groups, L-DOPA administration was continued for 6 days
after TAT cell-permeable peptides (CPPs) injection. To evaluate the ef-
fects of these CPPs on LIDs, behavioral assessments (AIMs score) on
TAT-2A-40/TAT-Scr-injected rats were carried out in double-blinded
conditions the day before the surgery (18 h before CPPs intrastriatal in-
jection, i.s.), on the day of the surgery (6 h after CPPs i.s.) and the follow-
ing days (30, 78 and 150 h after CPPs i.s.).
Forelimb akinesia was assessed using a modified version of the
stepping test (Paillé et al., 2010). Briefly, the experimenter firmly
suspended the rat's hindquarters so that the animal supported itsweight
on its forelimbs. Then, the experimenter moved the rat backwards along
the table (0.9m in 5 s) three consecutive times per session. For each ses-
sion, the total score calculated was the sum of the number of adjusting
steps observed in the three tests (for the contralateral paw). The number
of adjusting steps (ratio contralater/ipsilateral forelimbs) were counted
as a measure of forelimb akinesia. All sessions were video recorded and
analysed by an investigator blinded to the treatment received by the rat.
2.2. MPTP monkey model
Captive bred female monkeys (Macaca mulatta; Xierin, Beijing, mean
weight, 4.2 kg; mean age, 6.1 years) were housed in individual cages
under controlled conditions of humidity, temperature, and light. Food
and water were available ad libitum, and animal care was supervised
by veterinarians skilled in healthcare and maintenance. Experiments
were carried out in accordance with European Communities Council Di-
rective of 3 June 2010 (2010/6106/EU) for care of laboratory animals in
an Association for Assessment and Accreditation of Laboratory Animal
Care–accredited facility. Procedures were approved by the Institute of
Laboratory Animal Science ethical committee.
Macaques received daily saline or MPTP hydrochloride injections
(0.2 mg/kg, intravenously) until parkinsonian signs appeared as previ-
ously described (Porras et al. 2012; Santini et al. 2010; Shen et al.
2015; Urs et al. 2015; Ahmed et al. 2010). Once PDmotor signswere sta-
ble in MPTP-treated monkeys (n= 10), animals were either untreated
(n = 5) or treated twice daily with individually titrated dose of L-
DOPA that provided maximum reversal of parkinsonian motor signs
(Madopar, L-DOPA/carbidopa, 4:1 ratio; range, 9–17 mg/kg) (n = 5).
This dose of L-DOPA, defined as 100% dose, was used for chronic L-
DOPA treatment, which lasted for 4 to 5 months until dyskinesia
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Shen et al. 2015; Urs et al. 2015; Ahmed et al. 2010). TheMPTP intoxica-
tion protocol, the chronic L-DOPA treatment, the clinical assessments,
the terminal procedure and the characterization of the extent of
nigrostriatal denervation were conducted as previously published
(Porras et al. 2012; Santini et al. 2010; Shen et al. 2015; Urs et al. 2015;
Ahmed et al. 2010). As previously reported (Fernagut et al. 2010), DAT
binding autoradiography using [125I]-(E)-N-(3-iodoprop-2-enyl)-2ß-
carboxymethyl-3ß-(4′-methylphenyl)-nortropane (Chelatec, France)
showed a dramatic and similar reduction (N95%) in all MPTP-treated
groups in comparison to control animals (data not shown). Brain patches
collected from 300 μm-thick fresh frozen coronal sections containing
cortex and caudate-putamen were then further used for qPCR and WB.
2.3. Human tissue
Superior frontal gyrus samples from post-mortem brains of non-
demented control (n = 10) and Parkinson's disease patients (n = 10)
were obtained from The Netherlands Brain Bank (NBB) of Amsterdam
(https://www.brainbank.nl). All tissues were frozen as fast as possible
after death. Post mortem delays, age of PD diagnosis, age of death and
L-DOPA treatment duration are listed in Table 1. In accordance with
the international declaration of Helsinki, the NBB obtained written per-
mission from the donors for brain autopsy and the use of brain material
and clinical information for research purposes. All human data were
analysed anonymously.
2.4. CPPs
TAT-2A-40 peptide corresponding to GluN2A C-terminal domain
1349–1389 (EDSKRSKSLLPDHASDNPFLHTYQDDQRLVIGRCDSDPYKH)
fused to the TAT sequence (YGRKKRRQRRR) and corresponding scramble
peptide (YGRKKRRQRRR-LDPHSNPLYCPDLYSERFDVSKDHRLDKTKSDH
AQDRASIG) were synthetized by Bachem (Bubendorf, Switzerland). Ly-
ophilized CPPs were solubilized in sterile dH2O to a stock concentration
of 1 mM and stored at−20 °C before use.
2.5. Antibodies
The following unconjugated primary antibodies were used: mouse
monoclonal (mAb) anti-PSD-95 (Neuromab,); rabbit polyclonal (rAb)Table 1
Demographic table summarizing the data of patients from which brain samples were ob-
tained; PMD, post mortem delay.
# Diagnostic
group
Age
(years)
PMD
(h)
pH
liquor
Age of PD
diagnosis
L-Dopa treatment
duration (y)
Sex
1 NC 88 7 6.76 M
2 NC 79 6.3 6.32 M
3 NC 87 6.05 6.96 M
4 NC 88 4.43 6.17 M
5 NC 83 5.45 6.35 M
6 NC 79 5.45 6.38 M
7 NC 90 5.45 6.35 M
8 NC 79 6.30 6.71 M
9 NC 89 6.50 6.23 M
10 NC 83 5.15 6.60 M
11 PD 87 3.40 6.33 66 7 M
12 PD 86 5.35 6.19 60 25 M
13 PD 83 6.20 6.71 77 6 M
14 PD 81 5.15 6.78 60 16 M
15 PD 84 6.48 6 76 8 M
16 PD 82 6.05 6.09 79 3 M
17 PD 81 4.30 6.42 71 10 M
18 PD 86 7.25 6.26 70 1 M
19 PD 86 4.10 6.91 83 2 M
20 PD 86 6.15 6.33 80 6 M
Abbreviations: NC, non-PD control; PD, Parkinson's Disease patients; PMD, post-mortem
delay; y, years; h, hours; PMD, post-mortem delay; M, male.anti-GluN2A (Sigma-Aldrich,) andmAb anti-α-tubulin (Sigma-Aldrich);
rAb anti-DARPP-32 (Cell Signaling Technology); goat polyclonal anti-
ChAT (Novus Biologicals); rAb anti-Rph3A (Abcam); mAb anti-Rph3A
(ECM biosciences); rAb anti-P-Ser234 Rph3A (Phospho Solutions Auro-
ra); rAb anti-Rab3A (Abcam); CaMKII (Millipore,); Histone H3
(Proteintech); GluA1(Neuromab) e GluA1 P-845 (Millipore).
2.6. Quantitative PCR analysis
Total RNAwas extracted from animals and post-mortem PD patients
by using RNeasy mini kit (Qiagen), according to the manufacturer's in-
structions. 500 ng of total RNAs of each sample was reverse-
transcribed with Transcriptor First Strand cDNA Synthesis Kit (Roche)
using and RandomHexamer primer according to themanufacturer's in-
structions. qRT-PCR amplifications were performed using LightCycler
480 SYBR Green I Master in a LightCycler 480 Real Time thermocycler
(Roche).
2.7. Triton insoluble postsynaptic fraction (TIF) purification
Triton-insoluble fraction (TIF) was isolated from rat cortex, striatum,
hippocampus and cerebellum. This fraction is highly enriched in post-
synaptic density proteins and does not contain any presynaptic marker
(Gardoni et al. 2006). Samples were homogenized at 4 °C in an ice-cold
buffer containing 0.32 M Sucrose, 1 mM Hepes, 1 mM NaF, 0.1 mM
phenylmethylsulfonyl fluoride (PMSF), 1 mMMgCl supplemented with
protease inhibitors (Complete™, Sigma) and phosphatase inhibitors
(PhosSTOP™, Sigma). The homogenate was centrifuged at 1000g for
5min at 4 °C to remove nuclear contamination andwhitematter. The su-
pernatant was collected and centrifuged at 13,000g for 15 min at 4 °C.
The resulting pellet (P2 - crude membrane fraction) was resuspended
in hypotonic buffer (1 mM Hepes) and centrifuged at 100,000g for 1 h
at 4 °C. Triton-X-100 extraction of the resulting pellet was carried out
at 4 °C for 15 min in 1% Triton-X-100 and 75 mM KCl. The samples
were finally centrifuged at 100,000g for 1 h at 4 °C and the pellet obtain-
ed representing the TIF were resuspended in 20 mM HEPES.
2.8. Postsynaptic density (PSD) purification
Postsynaptic densities (PSDs) were isolated from rat striata. Striata
were dissected within 2 min from sacrifice and immediately frozen to
limit protein degradation. Homogenization was carried out in a glass-
Teflon homogenizer (700 rpm) in 4ml/g of cold 0.32M sucrose contain-
ing 1 mM HEPES, 1 mM MgCl2, 1 mM NaHCO2, and 0.1 mM PMSF
(pH 7.4), protease inhibitors (Complete™, Sigma) and phosphatase in-
hibitors (PhosSTOP™, Sigma). The homogenized tissue was centrifuged
at 1000g for 10 min. The resulting supernatant (S1) was centrifuged at
13,000g for 15 min to obtain a P2 crude membrane fraction. The pellet
was resuspended in 2.4 ml/g of 0.32 M sucrose containing 1 mM
HEPES, 1mMNaHCO3, and 0.1mMPMSF, overlaid on a sucrose gradient
(0.85–1.0–1.2 M), and centrifuged at 82,500g for 2 h. The fraction be-
tween 1.0 and 1.2 M sucrose (synaptosomal plasma membranes, SPM)
was removed and diluted with an equal volume of 1% Triton-X-100
and 0.32 M sucrose containing 1 mM HEPES. This solution was spun
down at 82,500 g for 45 min. The pellet (PSD1) was resuspended,
layered on a sucrose gradient (1.0–1.5–2.1 M), and centrifuged at
100,000g at 4 °C for 2 h. The fraction between 1.5 and 2.1 M was re-
moved and diluted with an equal volume of 1% Triton-X-100 and
150 mM KCl. PSD2 were finally collected by centrifugation at
100,000g at 4 °C for 45 min and stored at−20 °C until use.
2.9. Co-immunoprecipitation assay
50 μg of proteins from P2 - crude membrane fraction were incubated
for 1 h at 4 °C in RIA buffer containing 200 mM NaCl, 10 mM EDTA,
10 mM Na2HPO4, 0.5% Nonidet P-40 supplemented with 0.1% sodium
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TX, USA) as pre-cleaning procedure. The beadswere then let to sediment
at the bottom of the tube and the supernatant was collected. Primary an-
tibodies were added to the supernatant before leaving to incubate over-
night at 4 °C on a wheel. Protein A/G-agarose beads were added and
incubation was continued for 2 h, at room temperature on a wheel.
Beads were collected by gravity and washed three times with RIA buffer
before adding sample buffer for SDS–polyacrylamide gel electrophoresis
(SDS–PAGE) and themixturewas boiled for 10min. Beadswere pelleted
by centrifugation, all supernatants were applied onto 7–12% SDS–PAGE
gels
2.10. Pre-embedding immunocytochemistry
Sprague Dawleymale rats (n=3) of approximately 150–175 g were
used. Animals were perfused with 4% paraformaldehyde (PFA) and 0.1%
glutaraldehyde in 0.1 M phosphate buffered saline (PBS, pH 7.2), and
brain sections (100 μm) were cut on a Leica VT1000S vibratome (Leica
Microsystems, Milton Keynes, UK). All procedures were performed ac-
cording to the requirements of the United Kingdom Animals (Scientific
Procedures) Act 1986 and to the current European Law. The
immunolabeling method was previously described (Moreau et al.
2010; Piguel et al. 2014). Briefly, the sections were immunolabeled
with rAb anti-Rph3A (1:100; ab68857, Abcam), followed by a biotinylat-
ed secondary antibody, ABC Elite Kit (Vector Laboratories). The peroxi-
dase reaction was revealed by ImmPACT VIP substrate Kit (Vector
Laboratories). Then the sections were osmicated, dehydrated, and flat
embedded in Durcupan resin (Sigma-Aldrich). Ultrathin sections
(70–90 nm) were countercolored with uranyl acetate and lead citrate.
Control experiments, inwhich the primary antibodywas omitted, result-
ed in no immunoreactivity.
2.11. Free-floating immunohistochemistry (IHC)
Adult male rats were perfusedwith 4% PFA in PBS. The brainwas dis-
sected and post-fixed in 4% PFA in PBS for 2 h at 4 °C. Coronal slices (50
μm) containing the striatal region were obtained with Vibratome 1000
Plus Sectioning System (3 M). Brain slices were rapidly washed in PBS
(3 × 10min at RT) and blocked in 0.3% Triton X-100 in PBS (T-PBS) sup-
plemented with 10% normal goat serum or normal donkey serum (NGS
or NDS) for 1 h at RT. Coronal sliceswere then incubatedwith the appro-
priate primary antibody in 0.1% T-PBS with 3% NGS or NDS o/n at 4 °C.
Brain slices were washed in PBS (3 × 10 min at RT) and incubated with
the appropriate Alexa Fluor®-conjugated secondary antibody in 0.1% T-
PBS with 3% NGS or NDS for 2 h at RT. Nuclei were stained with the fluo-
rescent dye 4′,6-diamidino-2-phenylindole (DAPI, 1:500,000 in PBS,
Thermo Fischer Scientific). Finally, slices were mounted with
Fluoromount mounting medium (Sigma-Aldrich) on a Superfrost Plus
glass slide (VWR International, Leuven, Belgium). Labelling was visual-
ized with the LSM510 Metasystem Confocal Microscope (Zeiss,
Oberkochen, Germany) and AIM 4.2 software (Zeiss) using 40× objec-
tive and sequential acquisition setting at 1024 × 1024 pixel resolution.
2.12. Corticostriatal slices
Eight-week-oldmale Sprague-Dawley ratswere decapitated and the
brain was quickly removed from the skulls. Consecutive corticostriatal
slices were cut with Vibratome 1000 Plus Sectioning System (3 M)
(270 μm thick). Slices were then pre-incubated in Kreb's buffer
(124 mM NaCl, 3.3 mM KCl, 1.2 mM KH2PO4, 1.3 mM MgSO4, 2.5 mM
CaCl2, 20 mM NaHCO3 and 10 mM glucose, continuously equilibrated
with 95% O2 and 5% CO2) for 1 h. Then slices were treated with
SKF38393 (10 μM) or Ropinirole (100 nM) for 45 min at room temper-
ature continuously equilibrated with 95% O2 and 5% CO2. Control slices
were maintained in the vehicle alone. After treatment, striatal areaswere carefully isolated from the slices and then frozen on dry ice formo-
lecular studies.
2.13. Statistics
Data were analyzsd using GraphPad Prism version 6 (GraphPad Soft-
ware, La Jolla, CA, USA). Data followed a normal distribution and the sig-
nificance of the differences was analysed by unpaired two-tailed
Student's t-test/one-way or two-way ANOVA followed by Bonferroni or
Tukey post-hoc tests as appropriate. Details of the statistical analysis ap-
plied in thiswork and the p values are given in theResults section and/or
in the Figure legends. Data are presented as mean ± SEM.
3. Results
3.1. Rph3A characterization in the rat striatum
Aputative role for Rph3A in central nervous systemdisorderswith al-
terations in motor behaviour has been put forward (Chung et al. 2009;
Dalfó et al., 2004; Smith et al. 2005, 2007). However, only very few stud-
ies addressed the expression and the function of Rph3A in the striatum
(Chung et al. 2009) and the analysis of Rph3A in specific striatal cell-
types as well as its pre/postsynaptic localization in the striatum are lack-
ing. As shown in Fig.1A, a Rph3A protein band is distinctly detectable in
the homogenate and Triton-insoluble postsynaptic fractions (TIF) from
different rat brain areas, including cortex, striatum, hippocampus and
cerebellum. Using a validated subcellular fractionation method
(Gardoni et al. 2001, 2006) we purified excitatory postsynaptic densities
(PSDs) from rat striatum and we found that Rph3A is enriched in all
membrane fractions, including the PSD fractions (Fig. 1B) similar to
GluN2A. Conversely, Rab3A, a known Rph3A-interacting protein at the
presynaptic terminal (Burns et al. 1998), was present in several subcellu-
lar compartments analysed but not in the PSD fractions (Fig. 1B). More-
over, co-immunoprecipitation (co-i.p.) assay showed that, in the
striatum, Rph3A interacts with GluN2A subunit and PSD-95, similarly
to what has been described in the hippocampus (Fig. 1D; Stanic et al.
2015). Electron microscopy showed the presence of Rph3A in the den-
dritic shaft of striatal interneurons (Fig. 1C, left panel) and in dendritic
spines of medium spiny neurons (MSNs), mainly in proximity of excit-
atory synapses identified by their PSD (Fig. 1C, right panel). Confocal im-
aging confirmed striatal Rph3A to be expressed in bothMSNs (DARPP-32
positive cells; Fig. 1E) and cholinergic interneurons (ChAT positive cells;
Fig. 1F).
3.2. Influence of dopamine activation on Rph3A expression, Ser234 phos-
phorylation and interactionwith GluN2A in the postsynaptic compartment.
It has been demonstrated that treatment with D1 but not D2 dopa-
mine receptor agonists leads to a reduction of GluN2A-containing
NMDARs in postsynaptic compartment of MSNs (Vastagh et al. 2012).
Taking into account the role of Rph3A in the synaptic retention of
GluN2A-containing NMDARs (Stanic et al. 2015) we assessed Rph3A in-
volvement in this process. Treatment of corticostriatal slices with D1 ag-
onist SKF38393 (10 μM, 45 min) induced a significant reduction of
Rph3A in a Triton-insoluble postsynaptic fraction (TIF) (Fig. 2A; **p =
0.0069, SKF38393 versus Control, unpaired Student's t-test, n= 5) and
a concomitant increase of PKA-dependent Rph3A Ser234 phosphoryla-
tion (Fig. 2A; **p= 0.005, SKF38393 versus Control, unpaired Student's
t-test, n=4). These results were correlatedwith a decreased interaction
with GluN2A (Fig. 2B; ***p= 0.001, SKF38393 versus Control, unpaired
Student's t-test; n=5). Interestingly, this effect is specific to D1 receptor
activity as no change in Rph3A synaptic localization and interactionwith
GluN2A was observed after treatment with D2 receptor agonist
Ropirinole (100 nM, 45 min) (Fig. 2C–D; Rph3A WB in TIF: p= 0.4769,
Ropirinole versus Control, unpaired Student's t-test, n = 5; P-Ser234-
Rph3A WB in TIF: p = 0.6810, Ropirinole versus Control, unpaired
Fig. 1.Characterization of Rph3A in rat striatum. (A)Western blot (WB)of Rph3A inhomogenate and TIF fractions fromdifferent brain areas: Cx, cortex; St, striatum;Hp, hippocampus; Cb,
cerebellum. (B) Subcellular expression of GluN2A, Rph3A, CaMKII, Rab3A and Histone H3 in rat striatum. H, homogenate; S1/2, supernatant 1/2; P1/2, pellet 1/2; SPM, synaptosomal
plasma membrane fraction; PSD1/2, postsynaptic density fraction 1/2. (C) Immunolabeling of Rph3A in aspiny dendrites of interneurons (left panel) and spines of medium spiny
neurons (right panel). Electron microscopy image shows that Rph3A is found in the dendritic shaft of interneurons (left panel) and in spines of spiny neurons (right panel), as well as
in proximity of excitatory synapses identified by their PSD. Scale bar: 335 nm (left panel), 200 nm (right panel). (D) Co-immunoprecipitation experiments on rat striatal TIF fractions
using polyclonal GluN2A, monoclonal PSD-95 and polyclonal Rph3A antibodies show that GluN2A interacts with Rph3A also in the striatum. (E) Immunohistochemistry for Rph3A
(green) and DARPP-32 (MSN marker, red) in the adult rat striatum. Nuclei were visualized with DAPI (blue). Rph3A co-localizes with DARPP-32+ cells. Scale bar, 10 μm.
(F) Immunofluorescence for Rph3A (green) and ChAT (cholinergic interneuron marker, red) in the adult rat striatum. Nuclei were labeled with DAPI (blue). Rph3A is also co-localizing
with ChAT+ cell. Scale bar, 10 μm.
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sus Control, unpaired Student's t-test, n= 5).
3.3. Rph3A expression in rat, monkey models of PD and human patients
with PD
Considering the involvement of Rph3A in the synaptic stabilization of
GluN2A-containing NMDARs in the hippocampus (Stanic et al. 2015)
and the exacerbated postsynaptic localization of these receptor subtypes
in several experimental models of LIDs as well as in parkinsonian pa-
tients expressing dyskinesias (Mellone et al. 2015), we evaluated
Rph3AmRNA and protein levels in PD patients (Table 1) and PD animal
models. Rph3AmRNA and protein expression levels were unchanged in
the whole striatal lysates from dopamine-denervated and dyskinetic
rats (Fig. 3A; mRNA: F(2,9) = 1.539, p = 0.2661; protein: F(2,9) =
0.3209, p = 0.7335, one-way ANOVA), while MPTP-treated monkeysexhibited a significant reduction of Rph3AmRNA levels in caudate puta-
men, medial and superior frontal gyrus (Fig. 3B upper panels; caudate
putamen: F(2,12) = 5.098, p= 0.0250, one-way ANOVA; CTRL vs MPTP
group: p= 0.0383, Fisher's post-hoc comparison; medial frontal gyrus:
F(2,12) = 9.167, p= 0.0038; CTRL vs MPTP group: p= 0.0158; superior
frontal gyrus: F(2,12) = 4.759, p = 0.0301; CTRL vs MPTP group: p =
0.0189). In addition, Rph3AmRNA levels were also significantly reduced
in the caudate putamen and medial frontal gyrus of parkinsonian mon-
keys treated with L-DOPA (caudate putamen: CTRL vs MPTP + L-DOPA
group: p= 0.0303; medial frontal gyrus: p= 0.0066, Fisher's post-hoc
comparison, n=5), with a trend toward a reduction also in the superior
frontal gyrus (p= 0.0691). On the contrary, we did not observe a main
effect of the lesion, alone or in associatedwith L-DOPA supplementation,
on Rph3A protein levels in the aforementioned brain areas from parkin-
sonian and dyskinetic monkeys (Fig. 3B lower panels, p ≥ 0.05, for all
analysed groups, n = 5). In line with these observations, a significant
Fig. 2. Influence of dopaminergic pathway on Rph3A postsynaptic localization and its interactionwith GluN2A. (A)WBanalysis of Rph3A, P-Ser234-Rph3A and tubulin from the striatal TIF
fraction obtained from control (C) and SKF38393-treated (10 μM, 45min) corticostriatal slices. The same amount of protein was loaded in each lane. The bar graph shows the amount of
Rph3A and P-Ser234-Rph3A in the TIF fraction from SKF38393-treated slices (t-test; **p b 0.01; *p b 0.05). (B) Total homogenate was immunoprecipitated (i.p.) with antibody against
Rph3A and the presence of GluN2Ain the immunocomplex was evaluated by Western blot. Treatment with SKF38393 reduces GluN2A co-precipitation with Rph3A (t-test; ***p b
0.001). (C) WB analysis of Rph3A, P-Ser234-Rph3A and tubulin from the striatal TIF fraction obtained from control and ropinirole (100 nM, 45 min) corticostriatal slices. The same
amount of protein was loaded in each lane. The bar graph shows the amount of Rph3A and P-Ser234-Rph3A in the TIF fraction from ropinirole-treated slices. (D) Total homogenate
was immunoprecipitated (i.p.) with antibody against Rph3A and the presence of GluN2A in the immunocomplex was evaluated by Western blot. Treatment with ropinirole does not
modify GluN2A co-precipitation with Rph3A.
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rior frontal gyrus of post-mortem brain samples from PD patients
(Fig. 3C, p=0.0498, Mann-Whitney test, n= 10). Overall, these results
demonstrate no alterations of Rph3Aprotein levels in the total striatal ly-
sates from experimental models of PD and LID as well as in PD patients.
3.4. Rph3A synaptic localization and interaction with GluN2A-containing
NMDARs in the rat model of PD and L-DOPA-induced dyskinesia.
Taking into account that Rph3A plays a key role in the postsynaptic
compartment in the stabilization of GluN2A-containing NMDARs
(Stanic et al. 2015), we evaluated its postsynaptic localization and the
formation of Rph3A/GluN2A complex. WB analysis performed in the
rat striatal postsynaptic fraction revealed an increased synaptic localiza-
tion of Rph3A in L-DOPA-treated dyskinetic rats (Fig. 4A, left graph;
F(2,33) = 3.736, p=0.0348, one-way ANOVA, Tukey's post-hoc compar-
ison; DYS versus Control, *p ≤ 0.05). In addition, a significant decrease in
Rph3A Ser234 phosphorylation at synapses was found in dyskinetic an-
imals compared to controls (Fig. 4A, right graph; F(2,18) = 4.048, p =
0.0453, one-way ANOVA, Tukey's post-hoc comparison; DYS versus Con-
trol, *p ≤ 0.05). This phosphorylation is known to reduce the affinity of
Rph3A for membranes regulating its subcellular localization (Fykse
et al. 1995; Foletti et al. 2001). Finally, co-immunoprecipitation in striatal
homogenates from control, parkinsonian and dyskinetic rats showed
augmented GluN2A/Rph3A interaction in the dyskinetic experimental
group (Fig. 4B; F(2,24) = 13.39, p = 0.0004, one-way ANOVA, Tukey's
post-hoc comparison; DYS versus Control, ***p ≤ 0.001; DYS vs 6-
OHDA, *p ≤ 0.05).
3.5. Modulation of Rph3A/GluN2A complex in L-DOPA treated dyskinetic
rats.
The above results show an increase of Rph3A synaptic levels and its
interaction with GluN2A in L-DOPA-treated dyskinetic rats, thus provid-
ing a novel molecular mechanism responsible for the aberrant GluN2A
synaptic abundance which characterize experimental models of LIDs
and dyskinetic PD patients (Gardoni et al. 2012; Mellone et al. 2015).We previously characterized a cell-permeable peptide (TAT-2A-40)
able to interfere GluN2A/Rph3A complex by competing with GluN2A
for the binding to Rph3A (Stanic et al. 2015). In hippocampal neurons,
this disruption by TAT-2A-40 leads to a reduction in GluN2A-
containing NMDARs at the synaptic plasma membrane (Stanic et al.
2015). We therefore hypothesized that TAT-2A-40 could be useful to re-
duce synaptic GluN2A in dyskinetic rats potentially blocking abnormal
motor behaviour (see experimental schedule in Fig. 5). To this, we first
confirmed by co-immunoprecipitation assay the capability of TAT-2A-
40 to disrupt GluN2A/Rph3A interaction following intrastriatal injection.
We observed a significant reduction of the GluN2A/Rph3A complex after
TAT-2A-40 injection compared to the control scramble peptide in naïve
rat striata (Fig. 6A; *p = 0.0107, TAT-2A-40 versus TAT-Scr, n = 3) as
well as in dyskinetic rat ipsilateral striata (Fig. 6B; *p = 0.0358, TAT-
2A-40 versus TAT-Scr, n=7).We then evaluated whether acute admin-
istration of TAT-2A-40 to dyskinetic rats after chronic treatment with L-
DOPA could have beneficial effects on their abnormal motor behaviour.
TAT-2A-40 (n=8; 5 nmol) or TAT-Scr control (n=8; 5 nmol) peptides
were stereotaxically injected in the ipsilateral striatum of 6-OHDA-
lesioned rats chronically treated with L-DOPA and displaying dyskinetic
motor behaviour (Fig. 5). A group of dyskinetic animals continued the
treatment with L-DOPA alone (n=6). Peptides were injected 6 h before
the daily L-DOPA administration and the evaluation of AIMs was carried
out from 20 to 140min after L-DOPA (Fig. 6C–G). TAT-2A-40was able to
induce a significant reduction of the AIMs score compared to TAT-Scr
control group as well as the untreated dyskinetic group the effect lasting
until 150 h after injection (Fig. 6C–G).Moreover, the time course of AIMs
development showed that TAT-2A-40 significantly decreased AIMs in-
duction measured during the sessions taking place 6 h (Fig. 6E), 30 h
(Fig. 6F) and 150 h (Fig. 6G) after surgery. No differences were observed
in rats treated with TAT-Scr control peptide compared to untreated dys-
kinetic rats, thus demonstrating the absence of any effect induced by the
surgery procedure or by the TAT-Scr moiety (Fig. 6C–G). Moreover, no
change was induced by TAT-2A-40 or TAT-Scr on the anti-parkinsonian
effect of the L-DOPA treatment as evidence by the stepping test, a well-
knownmotor task used to assessmotor function, performedon these an-
imals (Fig. 6H).
Fig. 3. Rph3A expression levels in parkinsonian animal models and PD patients. (A) Striatal Rph3AmRNA (left) and protein (right) levels were analysed in 6-OHDA-lesioned rats, with or
without dyskinesias (n= 4). (B) Rph3AmRNA (upper) and protein (lower) expression levels in the homogenates of Caudate Putamen, Medial Frontal Gyrus and Superior Frontal Gyrus
from MPTP-treated monkeys, with or without L-DOPA supplementation (n= 5). (C) Evaluation of Rph3A mRNA (left) and protein (right) levels in the Superior Frontal Gyrus of post-
mortem PD patients from the Netherlands Brain Bank (n= 10).
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phorylation of Ser845-GluA1 subunit of the AMPA receptor as well-
known molecular marker of LIDs at the glutamatergic striatal synapse
(Ghiglieri et al. 2016). As shown in Fig. 6I, TAT-2A-40 treatment de-
creased the phosphorylation levels of this AMPA receptor phosphosite
compared to TAT-Scr (*p= 0.0474, TAT-2A-40 versus TAT-Scr, n= 7),
indicating a normalization of this molecular marker of dyskinesia corre-
lated to the PKA activity downstream D1 dopamine receptor (Santini
et al. 2010).
4. Discussion
Among the modifications of the striatal glutamatergic synapse in-
volved in L-DOPA-induced dyskinesia, several reports demonstrated
changes in NMDAR activity and subunit composition at MSNs dendritic
spines (Gardoni and Di Luca 2015; Bastide et al. 2015). In particular, our
previous studies clearly showed a direct correlation between an in-
crease GluN2A/GluN2B ratio at the corticostriatal synapse and the
onset of the abnormal involuntary movements both in animal models
and in PD patients (Gardoni et al. 2006, 2012; Mellone et al. 2015).
Here we demonstrate that Rph3A plays a key role in the aberrant
synaptic localization of GluN2A-containing NMDARs in L-DOPA-induced dyskinesias. In particular, we demonstrate that interfering
with Rph3A/GluN2A/PSD-95 complex at the synapse is strategic to cor-
rect the aberrant synaptic localization of GluN2A-containing NMDARs.
Different experimental approaches revealed that Rph3A is enriched at
the corticostriatal synapse where it interacts with the GluN2A subunit.
Notably, Rph3A expression at the postsynaptic density and its interac-
tion with GluN2A were increased in parkinsonian rats displaying a dys-
kinetic profile. Treatment of dyskinetic rats with a cell-permeable
peptide able to disrupt Rph3A/GluN2A interaction dramatically reduced
the L-DOPA-induced abnormal motormovements. Accordingly, Rph3A/
GluN2A complex could represent an innovative therapeutic target for
pathological conditions where NMDAR composition is significantly al-
tered such as PD and LIDs (Gardoni et al. 2006, 2012; Mellone et al.
2015).
Alterations in Rph3A immunoreactivity in different types of neurode-
generative disorders (Chung et al. 2009; Dalfó et al., 2004; Smith et al.
2005, 2007; Tan et al. 2014), including α-synucleinopathy, Alzheimer's
disease and Huntington's disease have been previously observed. In par-
ticular, these reports converge in indicating a downregulation of Rph3A
expression in different in vitro and in vivomodels of neurodegeneration.
We now show that Rph3AmRNA but not total protein levels in striatum
is downregulated in PD monkey model as well as in postmortem tissue
Fig. 4. Rph3A phosphorylation, synaptic localization and interaction with GluN2A in the rat experimental model of PD and LIDs (A)WB for Rph3A, pSer234-Rph3A and tubulin of striatal
TIF samples from the ipsilateral (6-OHDA) and the contralateral (Control) striata of 6-OHDA-lesioned rats and the ipsilateral striatumof L-DOPA-treated (6mg/kg/die) dyskinetic animals
(DYS). Rph3A and pSer234-Rph3A levels at synapses are altered in dyskinetic rats (*p ≤ 0.05). (B) Co-immunoprecipitation of GluN2A and Rph3A in P2 fractions from the ipsilateral (6-
OHDA) and the contralateral (Control) striata of 6-OHDA-lesioned rats and the ipsilateral striatum of L-DOPA-treated (6 mg/kg/die) dyskinetic rats (DYS) (***p b 0.001, *p b 0.05).
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the rat model of PD thus indicating the existence of a species-specific ef-
fect with alterations of Rph3A expression being more evident in pri-
mates. In particular, our data suggest a slow modulation of mRNA
levels following disease progression and chronic treatment with L-
DOPA. Accordingly, we observe an alteration of Rph3A mRNA levels
only after a long disease progression and a long-term exposure to the
drug as inmonkeys andhuman patients but not in the ratmodel, charac-
terized by a shorter time schedule of disease and treatment.
Our results show that chronic L-DOPA treatment leading to dyskine-
sia and pathological plasticity at the corticostriatal synapse (Calabresi
et al. 2016) leads to an increased accumulation of Rph3A at the postsyn-
aptic membranes and to a consequent enhanced Rph3A/GluN2A inter-
action. Several putative mechanisms could explain these molecularFig. 5. Schematic representation of the experimental plan applied for the injection of TAT-2alterations. It iswell-known that the onset of dyskinesia is linked to a se-
quence of events that include pulsatile stimulation of DA receptors,
changes in downstream signalling pathways and abnormalities in
non-DAergic transmitter systems (the glutamatergic synapse), all of
which converge to produce aberrant firing patterns that signal between
the basal ganglia and the cortex (Bastide et al. 2015). Among other
mechanisms, sensitized D1 receptor signalling is required for LIDs
onset, even if the specific role of the different molecular components
downstream D1 receptor still needs to be clarified (Bastide et al.
2015). In particular, recent studies suggest that Phospholipase C (PLC)
can mediate some of the effects of D1 receptor activation (Medvedev
et al. 2013) and mGluR5/PLC/PKC cascade can contribute as a potent
modulator of D1 receptor activation in the DA-denervated striatum
without altering D1-induced PKA activity (Fieblinger et al. 2014). InA-40 and TAT-Scr peptides in 6-OHDA-lesioned rats chronically treated with L-DOPA.
Fig. 6. Effect of modulation of GluN2A/Rph3A interaction in 6-OHDA rats displaying dyskinetic behaviour. (A) Coimmunoprecipitation of GluN2A with Rph3A from naïve rats treated 1 h
before with TAT-2A-40 (5 nmol) and TAT-Scr (5 nmol). P2 crude membrane fractions were immunoprecipitated (IP) with antibody against Rph3A and the presence of GluN2A in the
immunocomplex was evaluated by WB. Treatment with TAT-2A-40 reduces GluN2A co-precipitation with Rph3A (t-test, *p b 0.05). (B) Coimmunoprecipitation of GluN2A with Rph3A in
the striatum from dyskinetic animals at 30 h after TAT-2A-40 and TAT-Scr i.s. injection (5 nmol). P2 crude membrane fractions were immunoprecipitated (IP) with an antibody against
GluN2A and the presence of Rph3A in the immunocomplex was evaluated by WB. Treatment with TAT-2A-40 reduces Rph3A co-precipitation with GluN2A (t-test, *p ≤ 0.05).
(C) Decrease in the dyskinesia score (AIMs) of 6-OHDA rats treated with L-DOPA after 6 h, 30 h, 78 h and 150 h from the intrastriatal injection of TAT-2A-40 (two-way ANOVA F(8,86) =
2.186, *p= 0.0364; Tukey post hoc test, 6 h: ***p b 0.001, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, ***p b 0.001, L-DOPA - TAT-2A-40 versus L-DOPA; 30 h: ***p b 0.001, L-DOPA -
TAT-Scr versus L-DOPA - TAT-2A-40, ***p b 0.001, L-DOPA - TAT-2A-40 versus L-DOPA; 78 h: **p b 0.01, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, **p b 0.01, L-DOPA - TAT-2A-40
versus L-DOPA; 150 h: *p b 0.05, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40) or TAT-Scr. (D-G) Reduction of AIMs induction in TAT-2A-40 and TAT-Scr injected animals in the session
test 18 h before (D) and 6 h (E; two-way ANOVA F(12, 108) = 3.850, ***p b 0.0001; Tukey post hoc test, 40 min: *p b 0.05, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, **p b 0.01, L-
DOPA - TAT-2A-40 versus L-DOPA; 60 min: ***p b 0.001, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, ***p b 0.001, L-DOPA - TAT-2A-40 versus L-DOPA; 80 min: **p b 0.01, L-DOPA -
TAT-Scr versus L-DOPA - TAT-2A-40, ***p b 0.001, L-DOPA - TAT-2A-40 versus L-DOPA; 100 min: ***p b 0.001, L-DOPA - TAT-2A-40 versus L-DOPA; 120 min: *p b 0.05, L-DOPA - TAT-Scr
versus L-DOPA - TAT-2A-40), 30 h (F; two-way ANOVA F(12, 108) = 2.798, **p= 0.0023; Tukey post hoc test, 40 min: ***p b 0.001, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, ***p b
0.001, L-DOPA - TAT-2A-40 versus L-DOPA; 60 min: *p b 0.05, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, ***p b 0.001, L-DOPA - TAT-2A-40 versus L-DOPA; 80 min: *p b 0.05, L-
DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, **p b 0.01, L-DOPA - TAT-2A-40 versus L-DOPA; 100 min: *p b 0.05, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, *p b 0.05, L-DOPA - TAT-
2A-40 versus L-DOPA; 120 min: **p b 0.01, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, ***p b 0.001, L-DOPA - TAT-2A-40 versus L-DOPA), 150 h (G; two-way repeated measures
ANOVA F(12, 84) = 2.762, **p= 0.0033; Tukey post hoc test, 60 min: **p b 0.01, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, **p b 0.01, L-DOPA - TAT-2A-40 versus L-DOPA; 80 min:
**p b 0.01, L-DOPA - TAT-2A-40 versus L-DOPA; 100 min: **p b 0.01, L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40, **p b 0.01, L-DOPA - TAT-2A-40 versus L-DOPA; 120 min: **p b 0.01,
L-DOPA - TAT-Scr versus L-DOPA - TAT-2A-40) after CPP injection compared to animals treated only with L-DOPA. (H) The histogram shows the ratio contra/ipsi adjusting steps
measured with the stepping test performed 30 h after treatment treatment with TAT-2A-40 and TAT-Scr treated animals. (I) Striatal postsynaptic TIF fractions from TAT-2A-40 and TAT-
Scr treated animals were analysed by WB with GluA1 and GluA1-p845 antibodies. The histogram shows quantification of GluA1-p845/GluA1 ratio in the striatal TIF as percentage of TAT-
Scr animals (t-test, *p b 0.05).
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rats leading to aberrant calcium influx at dendritic spines of striatal
MSNs and the onset of pathological synaptic plasticity (Bastide et al.
2015). Interestingly, we recently showed that the concomitant presenceof calcium and IP3 induces a dramatic increase of Rph3A binding to
GluN2A (Stanic et al. 2015), indicating that both calcium and IP3 are
necessary for an efficient molecular recognition mechanism
(Coudevylle et al. 2008; Guillen et al. 2013; Montville et al., 2007).
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synaptic compartment of glutamatergic corticostriatal synapses togeth-
er with the increased postsynaptic levels of Rph3A can foster the
aberrant Rph3A/GluN2A complex formation observed in dyskinetic rats.
A directmolecular interaction and a functional cross-talk betweenD1
receptors and NMDARs in dendritic spines of MSNs have been reported
(Fiorentini et al. 2003; Jocoy et al. 2011; Ladepeche et al. 2013). We pre-
viously demonstrated that D1 receptor activation obtained with a classi-
cal receptor agonist, SKF38393, determines a significant decrease of
synaptic GluN2A-containing receptors (Vastagh et al. 2012). Interesting-
ly, here we show that D1 but not D2 receptor activation modulates
Rph3A synaptic localization, its Ser234 phosphorylation and its interac-
tion with GluN2A-containing NMDARs. In addition, our data show that
Ser234-Rph3A phosphorylation is reduced in dyskinetic rats compared
to controls thus suggesting that this post-translational modification
could be involved in the alteration of Rph3A synaptic localization ob-
served in dyskinetic animals. Notably, it is well-known that the phos-
phorylated form of Rph3A has a reduced affinity for membranes (Fykse
et al. 1995; Foletti et al. 2001) thus suggesting a possible explanation
for the enriched accumulation of the protein at the postsynaptic mem-
brane in dyskinetic rats.
Several observations converge in defining Rph3A as a pre- and post-
synaptic protein, involved in the regulation of protein localization at syn-
apses. Indeed, Rph3A directly binds proteins including the MAGUK
protein CASK and MyoVa, which are localized both in the pre- or post-
synaptic compartments and regulate protein trafficking (Brozzi et al.
2012).We recently demonstrated that Rph3A is required for synaptic re-
tention of GluN2A-containing NMDARs at the postsynaptic membrane
through the formation of a ternary complex with PSD-95 (Stanic et al.
2015). In particular, Rph3A is responsible for the strengthening of the
otherwise weak GluN2A/PSD-95 complex (Stanic et al. 2015; Gardoni
et al. 2001). Notably, we previously showed that interferingwith the for-
mation of GluN2A/PSD-95 complex leads to a reduction in the dyskinetic
motor behaviour in rodent and monkey models of LIDs (Gardoni et al.
2012; Mellone et al. 2015). Overall, these studies indicate that an inter-
vention on PSD-95 function is an efficient strategy to reduce LIDs at
least in experimental models. However, considering the large number
of protein-protein interactions involving PSD-95 at the excitatory synap-
se, a direct action on this scaffold protein does not represent an ideal
pharmacological approach because of problems of specificity and risk
of undesired side effects. Conversely, being PSD-95 and GluN2A the
only known partners for Rph3A at the postsynaptic compartment, inter-
fering with GluN2A/PSD-95/Rph3A protein complex could lead to a
more specific and direct approach tackling the aberrant NMDAR localiza-
tion and function in LIDs.
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